Valeo Pharma stock analysis
Valeo Pharma (VPHIF) Stock Price & Analysis
VPHIF Stock Chart & Stats
- Day’s Range
- $0.05 - $0.05
- 52-Week Range
- $0.05 - $0.05
- Previous Close
- $0.05
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $3.12M
- Enterprise Value
- $71.50M
- Total Cash (Recent Filing)
- $335.00K
- Total Debt (Recent Filing)
- $1.00M
- Price to Earnings (P/E)
- 0.0
- Beta
- -0.49
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Valeo Pharma News
VPHIF FAQ
What was Valeo Pharma’s price range in the past 12 months?
What is Valeo Pharma’s market cap?
When is Valeo Pharma’s upcoming earnings report date?
How were Valeo Pharma’s earnings last quarter?
Is Valeo Pharma overvalued?
Does Valeo Pharma pay dividends?
What is Valeo Pharma’s EPS estimate?
How many shares outstanding does Valeo Pharma have?
What happened to Valeo Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Valeo Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Valeo Pharma
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Al Moghaddam B. Cma
- Employees
- 70
- Website
- www.valeopharma.com
- Address
- 16667 Hymus Boulevard, Kirkland, QC, H9H 4R9, CA
Valeo Pharma (VPHIF) Earnings & Revenues
VPHIF Earnings Call
Earnings Call SentimentNeutral
The earnings call presented a mixed picture. While there were strong performances in the Respiratory and Specialty units, and cost-saving measures are progressing, the significant loss of revenue from the termination of Xiidra and increased net loss create challenges. The company is taking steps to improve financial flexibility and profitability, yet the overall situation remains challenging.
View all VPHIF earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 2 | 4 |
| Technical Analysis | 2 | 0 | 2 |
| Moving Averages | 2 | 2 | 2 |
